Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of Formula (I),



Formula (I)

wherein

A represents a direct bond or optionally substituted C_{1-5}alkylene;

B is a group of Formula (II):



Formula (II);

wherein at position (a) Formula (II) is attached to the nitrogen atom and the group **X** is attached to $\mathbf{R^8}$;

M is $-(CH_2)_{0-2}$-O-;

$\mathbf{R^1}$ represents hydrogen; optionally substituted C_{1-8}alkyl; or $(CH_2)_b$-$\mathbf{R^a}$, wherein

$\mathbf{R^a}$ represents C_{3-8}cycloalkyl and **b** is zero or an integer from 1 to 6;

$\mathbf{R^2}$ represents an optionally substituted mono- or bi-cyclic aromatic ring structure wherein the optional substituents are selected from cyano, $N\mathbf{R^3R^{3a}}$, optionally substituted C_{1-8}alkyl, optionally substituted C_{1-8}alkoxy or halo;

$\mathbf{R^3}$ and $\mathbf{R^{3a}}$ are independently selected from hydrogen; optionally substituted C_{1-8}alkyl and optionally substituted aryl;

$\mathbf{R^5}$ is selected from an optionally substituted 3 to 8 membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; or a group of formula **III-a**; **III-b**; **III-c**; **III-d**; **III-e; III-f**, **III-g** , **III-h**, **III-i** or[[:]] **III-j**[[;]];



III-a



III-b



III-c



III-d



III-e



III-f



III-g



III-h



III-i



III-j

wherein **het** represents an optionally substituted 3 to 8 membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S;

R^6 and R^{6a}, are independently selected from hydrogen and optionally substituted C_{1-8}alkyl; or R^6 and R^{6a} together represent carbonyl;

R^7 represents hydrogen or optionally substituted C_{1-8}alkyl;

or R^6⌒A-N-R^7 together from an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 3 further heteroatoms independently selected from O, N and S, and R^{6a} represents hydrogen ~~and~~ or optionally substituted C_{1-8}alkyl;

X and R^8 are selected from:

(i) **X** represents N and R^8 is selected from:
cyano, hydrogen, hydroxy, -O-R^b, –N$R^b R^c$ –C(O)O-R^b, –CON$R^b R^c$ or NH-C(O)-R^b, where R^b and R^c are independently selected from hydrogen and C_{1-4}alkyl optionally substituted with hydroxy, amino, N-C_{1-4}alkylamino, N,N-di-C_{1-4}alkylamino, HO-C_{2-4}alkyl-NH- or HO-C_{2-4}alkyl-N(C_{1-4}alkyl)-;

(ii) **X** represents CH and R^8 represents NO_2; and

(iii) **X**- R^8 represents –O-;

R^{11} is a group of the formula: $N(R^9R^{10})$ wherein R^9 represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted C_{1-8}alkyl and R^{10} represents hydrogen or optionally substituted C_{1-8}alkyl; or

the structure $N(R^9R^{10})$ represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S;

R^{12} and R^{12a} are independently selected from hydrogen or optionally substituted C_{1-8}alkyl; or R^{12} and R^{12a} together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;

R^{13} and R^{14} are selected from:

(i) R^{13} is selected from hydrogen; optionally substituted C_{1-8}alkyl; optionally substituted aryl; $-R^d$-Ar, where R^d represents C_{1-8}alkylene and Ar represents optionally substituted aryl; and optionally substituted 3 to 8 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and R^{14} is selected from hydrogen; optionally substituted C_{1-8}alkyl and optionally substituted aryl;

(ii) where R^5 represents a group of formula **III-a , III-b** or **III-i**, then the group $NR^{13}(-R^{14})$ represents an optionally substituted 3 to 8 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or

(iii) where R^5 represents structure **III-e**, then the group  represents an optionally substituted 3 to 8 membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;

or a salt, pro-drug or solvate thereof.

2. (Currently amended) A compound according to Claim 1 wherein R^9 represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted C_{1-8}alkyl and

R^{10} represents hydrogen or optionally substituted C_{1-8}alkyl

wherein the optional substituents on aryl, the heterocyclic ring and C_{1-8}alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3 to 8 membered heterocyclyl containing from 1 to 4 heteroatoms

independently selected from O, N and S, -O-**R**^{b}, C(O)N**R**^{b}**R**^{c}, -N**R**^{b}**R**^{c}, -N**R**^{c}C(O)-**R**^{b}, -C(O)N**R**^{b}**R**^{c}, -N**R**^{c}S(O_{0-2})**R**^{b}[[,]] and -S(O_{0-2})**R**^{b}, wherein **R**^{b} and **R**^{c} are as defined in Claim 1.

3. (Original) A compound according to Claim 2 wherein **R**^{9} is a C_{1-6}alkyl group substituted by pyridyl, thienyl, piperidinyl, imidazolyl, triazolyl, thiazolyl, pyrrolidinyl, piperazinyl, morpholinyl, imidazolinyl, benztriazolyl, benzimidazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, furanyl, pyrrolyl, 1,3-dioxolanyl or 2-azetinyl, each of which is optionally substituted.

4. (Original) A compound according to Claim 1 wherein the structure N(**R**^{9}**R**^{10}) represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S.

5. (Currently amended) A compound according to Claim 4 wherein the 3- to 10 membered heterocyclic ring is optionally substituted by one of more groups selected from **R**^{15} wherein **R**^{15} is selected from optionally substituted aryl, an optionally substituted 3 to 10 membered heterocyclic ring or optionally substituted C_{1-4}alkyl wherein the optional substituents on aryl, a heterocyclic ring or C_{1-4}alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3 to 8 membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, -O-**R**^{b}, C(O)N**R**^{b}**R**^{c}, -N**R**^{b}**R**^{c}, -N**R**^{c}C(O)-**R**^{b}, -C(O)N**R**^{b}**R**^{c}, -N**R**^{c}S(O_{0-2})**R**^{b}[[,]] and -S(O_{0-2})**R**^{b}, wherein **R**^{b} and **R**^{c} ~~are as defined in Claim 1~~ are independently selected from hydrogen and C_{1-4}alkyl optionally substituted with hydroxy, amino, N-C_{1-4}alkylamino, N,N-di-C_{1-4}alkylamino, HO-C_{2-4}alkyl-NH- or HO-C_{2-4}alkyl-N(C_{1-4}alkyl)-.

6. (Previously presented) A compound according to claim 1 wherein **R**^{5} is selected from a group of formula **III-a** , **III-g**, **III-h**, **III-i** or **III-j**:



III-a



III-g



III-h



III-i



III-j

7. (Previously presented) A compound according to claim 1 wherein **X** and R^8 are selected from

(a) **X** represents N and R^8 represents cyano or –C(O)O-R^b; or

(b) **X** represents N and R^8 represents hydrogen.

8. (Currently amended) A compound according to claim 1 wherein R^2 is selected from an optionally substituted monocyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR^3[[^{e}]]R^{3a}[[^{f}]], optionally substituted C_{1-8}alkyl, optionally substituted C_{1-8}alkoxy or halo wherein R^3[[^{e}]] and R^{3a}[[^{f}]] are independently selected from hydrogen, C_{1-6}alkyl or aryl.

9. (Previously presented) A compound according to claim 1 wherein R^1 is hydrogen.

10. (Currently amended) The compound:

3-[2,2-dimethyl-3-oxo-3-(7-azabicyclo[2.2.1]heptan-7-yl)propoxy~~yl~~]-4-[(1S)-1-methyl-2-[(~~N'-~~isopropoxycarbonyl)imino(-3-pyridin-4-yl-pyrrolidin-1-yl)methyl]~~carboximidamido)-~~aminoethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole;

or a salt, pro-drug or solvate thereof.

11. (Cancelled)

12. (Previously presented) A pharmaceutical formulation comprising a compound, or salt, pro-drug or solvate thereof, according to claim 1 and a pharmaceutically acceptable diluent or carrier.

13. (Cancelled)

14. (Previously presented) A process of producing a compound, or salt, pro-drug or solvate thereof, according to claim 1, wherein the process comprises a reaction step selected from any one of steps (a) to (f):-

(a) for compounds wherein **X** is N and R^8 is CN, reaction of a compound of formula **XXXII** as follows



XXXII **XXXIII**

(b) for compounds wherein **X** is N and R^8 is hydrogen, cleavage of the cyano group of compound of formula **XXXIII** in the presence of acid to produce compound of formula **XXXIV**



XXXIV

(c) for compounds wherein **X** is CH and R^8 is NO_2, reaction of compound of formula **XXXV** as follows



XXXV **XXXVI**

(d) for compounds where **X-R^8** is O, reaction of compound of formula **XXXVII** as follows



XXXIX **XXXX**

(e) for compounds where **X-R^8** is O, reaction of compound of formula **XXXIX** as follows



XXXIX **XXXX**

(f) to form a compound wherein **X** is nitrogen reaction of a compound of formula XXXXI as follows



XXXXI **XXXXII**

and thereafter if necessary:

i) converting a compound of the Formula (I) into another compound of the Formula (I);

ii) removing any protecting groups;

iii) forming a salt, pro-drug or solvate.